Novotech Named Best Australian CRO at Asia-Pacific Biopharma Excellence Awards

Novotech, which provides biotech and small- to mid-size pharmaceutical companies an accelerated path to market, has been named the best contract research organization (CRO) in Australia at the Asia-Pacific Biopharma Excellence Awards (ABEA) 2025 (1).

ABEA recognizes industry standouts in clinical trials as well as organizations, experts, and technologies that are helping to drive innovation (1). Voting is done 100% within the industry, according to a press release, to ensure that winners will be recognized by their peers.

"We thank the Asia Pacific Biopharma Excellence Awards for this recognition,” Chris Chong, Novotech senior director of Clinical Services, said while accepting the award at a ceremony in Singapore (1). “This award reflects the dedication of our teams worldwide who support biopharma innovation. Our clients and partners entrust us with their research, and we take pride in accelerating the development of new therapies. Novotech remains committed to advancing clinical research, strengthening partnerships, and maintaining high standards in biopharma development.”

Novotech has more than 30 offices globally with partnerships with more than 5000 trial sites, and, according to the press release, has been honored with Frost & Sullivan’s CRO Company of the Year award for 19 consecutive years (1).

Elsewhere in Australia so far in 2025, the Australian nonprofit Genetic Cures for Kids entered into a collaboration in January with United States-based CRO/contract development and manufacturing organization (CDMO) PackGene Biotech and the Belfer Gene Therapy Core Facility at Weill Cornell Medicine, to deliver an accessible, custom-tailored gene therapy solution for treating hereditary spastic paraplegia type 56, an ultra-rare neurological disease (2).

Also in January, North Melbourne-based Telix Pharmaceuticals announced it had entered into an asset purchase agreement with ImaginAb, an antibody engineering company, giving Telix a pipeline of next-generation therapeutic candidates, a proprietary and novel biologics technology platform, and a protein engineering and discovery research facility located in California (3).

In February, Sydney-based AdvanCell, a clinical-stage radiopharmaceutical company specializing in the development of cancer therapeutics, announced that it successfully completed an oversubscribed, $112 million round of Series C financing (4). And on February 20, Cosette Pharmaceuticals of Bridgewater, NJ, said it had an agreement in place to buy all remaining shares of Australia-based Mayne Pharma Group with two state-of-the-art, FDA-approved manufacturing sites to be operational as a result of the merger, in Salisbury, South Australia, and in Lincolnton, NC, in the United States (5).

References

1. Novotech. Novotech Named Best Contract Research Organization in Australia at Asia-Pacific Biopharma Excellence Awards 2025. Press Release. March 25, 2025.
2. PackGene Biotech. A Global Alliance to Save Lives: How Two Parents and PackGene Are Redefining What’s Possible in Gene Therapy with Help from Weill Cornell Medicine. Press Release. Jan. 8, 2025.
3. Telix Pharmaceuticals. Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform. Press Release. Jan. 13, 2025.
4. AdvanCell. AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing. Press Release. Feb. 3, 2025.
5. Cosette Pharmaceuticals. Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women’s Health and Dermatology. Press Release. Feb. 21, 2025.